MetaCap

Jyong Biotech (MENS) vs Spruce Biosciences (SPRB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Spruce Biosciences (SPRB) has outperformed Jyong Biotech (MENS) over the past year, losing 63.8% versus a loss of 95.3%. Jyong Biotech is the larger company by market cap ($110.2 million vs $109.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MENS-95.28%SPRB-63.81%
+21%-40%-101%
Nov 21, 20251 yearNov 20, 2026
MENS-81.90%SPRB-90.35%
+760%+311%-139%
Jun 16, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MENS versus SPRB key metrics
MetricMENSSPRB
Share price$1.45$38.00
Market cap$110.24M$109.21M
1-day change-17.14%-6.15%
YTD return-63.29%-56.38%
1-year return-95.28%-63.81%
5-year return—-99.75%
Forward P/E—11.79
EPS (TTM)$-0.06$-33.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-4.67M$-38.97M
52-week high$38.88$111.00
52-week low$1.43$38.00
Distance from 52-week high-96.27%-65.77%
Analyst consensus—strong_buy
Avg. price target upside—+288.00%
Average volume44.23K89.33K
Shares outstanding74.23M2.87M
Employees2725
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SPRB has outperformed MENS by 31.5 percentage points over the past year.

About Jyong Biotech

MENS stock →

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees

About Spruce Biosciences

SPRB stock →

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

MENS vs SPRB FAQ

Which is bigger, Jyong Biotech or Spruce Biosciences?

Jyong Biotech (MENS) is larger, with a market capitalization of $110.24M compared with $109.21M for Spruce Biosciences (SPRB).

Which stock has performed better over the past year, MENS or SPRB?

SPRB returned -63.81% over the past 12 months, compared with -95.28% for MENS (price return, excluding dividends). Past performance does not predict future results.

Are Jyong Biotech and Spruce Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons